136 related articles for article (PubMed ID: 36760122)
1. Inhibitory machinery for the functional dystroglycan glycosylation.
Kondo Y; Okajima T
J Biochem; 2023 Apr; 173(5):333-335. PubMed ID: 36760122
[TBL] [Abstract][Full Text] [Related]
2. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
Imae R; Manya H; Tsumoto H; Miura Y; Endo T
J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
[TBL] [Abstract][Full Text] [Related]
3. CDP-glycerol inhibits the synthesis of the functional
Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
[TBL] [Abstract][Full Text] [Related]
4. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
Elife; 2021 Jan; 10():. PubMed ID: 33513091
[TBL] [Abstract][Full Text] [Related]
5. Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth.
Lu PJ; Tucker JD; Branch EK; Guo F; Blaeser AR; Lu QL
Sci Rep; 2020 Mar; 10(1):4935. PubMed ID: 32188898
[TBL] [Abstract][Full Text] [Related]
6. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
[TBL] [Abstract][Full Text] [Related]
7. Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
Tamura JI; Tamura T; Hoshino S; Imae R; Kato R; Yokono M; Nagase M; Ohno S; Manabe N; Yamaguchi Y; Manya H; Endo T
ACS Chem Biol; 2022 Jun; 17(6):1513-1523. PubMed ID: 35670527
[TBL] [Abstract][Full Text] [Related]
8. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel monoclonal antibody against truncated glycoforms of α-dystroglycan lacking matriglycans.
Yamasaki F; Umezawa F; Sensui T; Anzo M; Abo H; Kuo CW; Khoo KH; Kato K; Yagi H; Kawashima H
Biochem Biophys Res Commun; 2021 Nov; 579():8-14. PubMed ID: 34583196
[TBL] [Abstract][Full Text] [Related]
10. Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.
Hoshino S; Manya H; Imae R; Kobayashi K; Kanagawa M; Endo T
J Biochem; 2024 Mar; 175(4):418-425. PubMed ID: 38140954
[TBL] [Abstract][Full Text] [Related]
11. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
Cataldi MP; Lu P; Blaeser A; Lu QL
Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
[TBL] [Abstract][Full Text] [Related]
12. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
Kanagawa M; Toda T
J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
[TBL] [Abstract][Full Text] [Related]
13. Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.
Umezawa F; Natsume M; Fukusada S; Nakajima K; Yamasaki F; Kawashima H; Kuo CW; Khoo KH; Shimura T; Yagi H; Kato K
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743105
[TBL] [Abstract][Full Text] [Related]
14. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
[TBL] [Abstract][Full Text] [Related]
16. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
[TBL] [Abstract][Full Text] [Related]
17. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
Tokuoka H; Imae R; Nakashima H; Manya H; Masuda C; Hoshino S; Kobayashi K; Lefeber DJ; Matsumoto R; Okada T; Endo T; Kanagawa M; Toda T
Nat Commun; 2022 Apr; 13(1):1847. PubMed ID: 35422047
[TBL] [Abstract][Full Text] [Related]
18. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
19. Fukutin-Related Protein: From Pathology to Treatments.
Ortiz-Cordero C; Azzag K; Perlingeiro RCR
Trends Cell Biol; 2021 Mar; 31(3):197-210. PubMed ID: 33272829
[TBL] [Abstract][Full Text] [Related]
20. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
Elife; 2023 Feb; 12():. PubMed ID: 36723429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
